Results 181 to 190 of about 6,720,476 (300)
Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients
Molecular Oncology, EarlyView.RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel +14 morewiley +1 more sourceInteraction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy
Molecular Oncology, EarlyView.Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen +9 morewiley +1 more sourceTree diversity is changing across tropical Andean and Amazonian forests in response to global change. [PDF]
Nat Ecol EvolFadrique B, Costa F, Cuesta F, Arellano G, Cayuela L, Baker TR, Draper FC, Esquivel-Muelbert A, Ter Steege H, Bauters M, Aguirre-Gutiérrez J, Aguirre-Mendoza Z, Alexiades MN, Alvarez-Davila E, Arets E, Ayala E, Aymard CGA, Baccaro F, Báez S, Baraloto C, Barbosa RI, Barbosa Camargo P, Barlow J, Barni PE, Barroso J, Benchimol M, Bennett AC, Berenguer E, Blanc L, Bonal D, Bongers F, Brienen R, Brown F, Bt Andrade M, Burban B, Burnham RJ, Camargo JL, Carvalho SPC, Castilho C, Chave J, Coelho de Souza F, Comiskey J, da Costa L, de Lima RB, de Oliveira EA, de Oliveira RLC, de Oliveira Perdiz R, De Rutte J, Del Aguila-Pasquel J, Derroire G, Di Fiore A, Disney M, Duque A, Emilio T, Farfan-Rios W, Fauset S, Fearnside PM, Feeley KJ, Feldpausch TR, Ferreira J, Ferreira L, Flores Llampazo GR, Galbraith D, García-Cabrera K, García Criado M, Gloor E, Grandez-Rios JM, Hérault B, Homeier J, Honorio Coronado EN, Huamantupa-Chuquimaco I, Huaraca Huasco W, Huillca-Aedo YT, Idárraga Á, Jadán-Maza O, Kalamandeen M, Killeen TJ, Laurance SGW, Laurance WF, Levesley A, Lopez W, Macía MJ, Magnusson WE, Malhi Y, Manzatto AG, Marimon BS, Marimon Junior BH, Martínez-Villa JA, Medeiros MB, Melgaço K, Melo L, Metzker T, Monteagudo A, Morandi PS, Myers JA, Nascimento HM, Nascimento R, Neill D, Nieto-Ariza B, Palacios WA, Palacios-Ramos S, Pallqui-Camacho NC, Pardo Molina G, Peacock J, Peña MA, Pennington RT, Peñuela MC, Peres CA, Pérez ÁJ, Pickavance GC, Pinto E, Pipoly J, Pitman N, Prieto A, Ramírez-Angulo H, Reis SM, Restrepo Z, Reynel C, Ribeiro S, Rivas-Torres G, Rojas R, Rudas A, Salinas N, Salomão RP, Santana F, Schietti J, Schwartz G, Serrano J, Silman M, Silva C, Silva CA, Silva RC, Silva RSA, Silva-Espejo J, Silveira M, Simon MF, Soto-Shareva YC, Souza PF, Storck-Tonon D, Stropp J, Swamy V, Tello JS, Terborgh J, Thomas R, Torres-Lezama A, Vale JD, Valenzuela Gamarra L, van der Heijden G, van der Hout P, van der Meer PJ, Vasquez Martinez R, Vedovato L, Verbeeck H, Vieira I, Vieira SA, Vilanova E, Vinceti B, Vos VA, Zagt R, Zuidema PA, Phillips OL. +160 moreeuropepmc +1 more sourceProteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer
Molecular Oncology, EarlyView.Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi +10 morewiley +1 more sourceIdentifying and addressing the anthropogenic drivers of global change in the North Sea: a systematic map. [PDF]
Environ EvidBlöcker AM, Auch D, Gutte HM, Biederbick J, Asselot R, Färber L, Börner G, Kamberi E, Madiraca F, Ofelio C, Steidle L, Moullec F. +11 moreeuropepmc +1 more sourceMolecular cancer prevention: Intercepting disease
Molecular Oncology, EarlyView.Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...Charlotte Grieco, Tej Pandya, Charles Swanton +2 morewiley +1 more sourceDNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients
Molecular Oncology, EarlyView.Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang +14 morewiley +1 more source